Cyclacel Pharmaceuticals Stock

Cyclacel Pharmaceuticals Employees 2024

Cyclacel Pharmaceuticals Employees

12

Ticker

CYCC

ISIN

US23254L6039

WKN

A2P26W

In 2024, Cyclacel Pharmaceuticals employed 12 people, a 0% change from the 12 number of employees in the previous year.

Cyclacel Pharmaceuticals Aktienanalyse

What does Cyclacel Pharmaceuticals do?

Cyclacel Pharmaceuticals Inc was founded in 1996 and is headquartered in Berkeley Heights, New Jersey. The company was established by Dr. David Glover, an experienced biotechnology expert, and Dr. Paul Andrews, an oncology pioneer. Cyclacel Pharmaceuticals is a company specializing in the research and development of cancer drugs. It has two main divisions: clinical drug development and drug discovery. The company's business model is to develop innovative cancer drugs to meet the needs of patients with various types of cancer. The company utilizes an innovative approach by researching and developing cyclin-dependent kinase inhibitors (CDKIs) that aim to exploit the specific vulnerabilities of cancer cells. Cyclacel Pharmaceuticals currently offers four products: Seliciclib, Sapacitabin, CYC065, and CYC140. Seliciclib is a CDKI inhibitor that is currently in clinical development and being studied in a phase 2 trial for advanced cancer patients. Sapacitabin is a CDKI stabilizer that is currently being studied in a phase 3 trial for patients with acute myeloid leukemia (AML). CYC065 is a CDKI inhibitor that is still in preclinical development and currently being tested in drug discovery. CYC140 is another CDKI target that is in preclinical development and aims to eliminate cancer cells. Cyclacel Pharmaceuticals has achieved many significant milestones in its history, including the FDA approval of Seliciclib and Sapacitabin as orphan drugs for the treatment of AML. The company has also formed important partnerships with other pharmaceutical companies to further develop and distribute its drug class. Overall, Cyclacel Pharmaceuticals pursues a promising strategy in the fight against cancer through the research and development of CDKI regulators. Although the company has only a few products on the market, it is well positioned to continue growing and developing innovative drugs that can improve patients' lives. Cyclacel Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Employees Details

Examining Cyclacel Pharmaceuticals's Employee Base

Cyclacel Pharmaceuticals's employees are a pivotal aspect of its operations, driving innovation, productivity, and growth. The size and composition of the workforce offer insights into the company's scale, diversity, and investment in human capital. Analyzing employee trends and data is essential for understanding Cyclacel Pharmaceuticals's operational capacity and future potential.

Year-to-Year Comparison

Assessing Cyclacel Pharmaceuticals's employee numbers year-over-year helps in identifying growth patterns, expansions, or contractions. An increasing employee count can indicate scaling operations and investment in talent, while a decrease may signal efficiency improvements, automation, or business challenges.

Impact on Investments

Cyclacel Pharmaceuticals's employee data impacts investment decisions by shedding light on the company’s operational efficiency, innovation capability, and sustainability. Investors assess workforce data to gauge the firm's potential to execute strategies, innovate, and adapt to market changes effectively.

Interpreting Employee Trends

Fluctuations in Cyclacel Pharmaceuticals’s employee numbers indicate changes in business strategy, operational demands, and market dynamics. Investors and analysts scrutinize these trends to evaluate the company’s strategic positioning, adaptability, and potential for sustainable growth.

Frequently Asked Questions about Cyclacel Pharmaceuticals stock

How many employees does Cyclacel Pharmaceuticals have this year?

Cyclacel Pharmaceuticals has 12 undefined employees this year.

How many employees did Cyclacel Pharmaceuticals have compared to the previous year?

Compared to the previous year, Cyclacel Pharmaceuticals had 0% more employees.

What impact did the number of employees have on the company Cyclacel Pharmaceuticals?

The number of employees has a direct impact on the efficiency and productivity of Cyclacel Pharmaceuticals. A higher number of employees can indicate that the company is growing and has more resources to achieve its goals, while a lower number of employees may suggest that the company is saving costs or facing difficulties in recruiting new employees.

What impact did the number of employees have on investors of Cyclacel Pharmaceuticals?

The number of employees can also have an impact on investors of Cyclacel Pharmaceuticals, as it can be an indicator of the company's growth and financial health. A higher number of employees can promise investors, while a lower number of employees may raise concerns.

How does an increase in equity capital of Cyclacel Pharmaceuticals affect the company?

An increase in equity of Cyclacel Pharmaceuticals can improve the financial strength of the company and increase its ability to make future investments and fulfill obligations.

How does a reduction in Cyclacel Pharmaceuticals's equity affect the company?

A reduction in equity of Cyclacel Pharmaceuticals can impair its financial stability and decrease its ability to fulfill future investments and obligations.

What are some factors that influence the equity of Cyclacel Pharmaceuticals?

Some factors that can influence the equity of Cyclacel Pharmaceuticals include, among others, revenue development, profit and loss statement, dividend payments, and investments.

Why is the equity of Cyclacel Pharmaceuticals so important for investors?

The equity of Cyclacel Pharmaceuticals is important for investors as it is an indicator of the company's financial stability and provides investors with information on the amount of financial backing the company has in terms of obligations and future investments.

How does the number of employees at Cyclacel Pharmaceuticals influence the company?

The number of employees at Cyclacel Pharmaceuticals can directly impact the growth and performance of the company. A higher number of employees can lead to increased capacity and productivity, while a lower number of employees may result in reduced efficiency and limitations.

How has the number of employees at Cyclacel Pharmaceuticals evolved in recent years?

In recent years, the number of employees at Cyclacel Pharmaceuticals has changed by 0.

How many employees does Cyclacel Pharmaceuticals currently have?

Cyclacel Pharmaceuticals currently has 12 undefined employees.

Why is the number of employees important for investors of Cyclacel Pharmaceuticals?

The number of employees is important for investors of Cyclacel Pharmaceuticals as it is an indicator of the growth potential and performance of the company. It also provides information on how the company is able to manage and recruit its workforce.

What strategic measures can Cyclacel Pharmaceuticals take to change the number of employees?

To change the number of employees, Cyclacel Pharmaceuticals can take various measures such as adjusting compensation packages, improving working conditions, conducting recruitment campaigns, and promoting a positive corporate culture. It is important for the company to conduct a thorough assessment of its situation to determine the best strategic actions to change its number of employees.

How much dividend does Cyclacel Pharmaceuticals pay?

Over the past 12 months, Cyclacel Pharmaceuticals paid a dividend of 0.15 USD . This corresponds to a dividend yield of about 14.56 %. For the coming 12 months, Cyclacel Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Cyclacel Pharmaceuticals?

The current dividend yield of Cyclacel Pharmaceuticals is 14.56 %.

When does Cyclacel Pharmaceuticals pay dividends?

Cyclacel Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Cyclacel Pharmaceuticals?

Cyclacel Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Cyclacel Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Cyclacel Pharmaceuticals located?

Cyclacel Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Cyclacel Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Cyclacel Pharmaceuticals from 8/1/2016 amounting to 0.15 USD, you needed to have the stock in your portfolio before the ex-date on 7/13/2016.

When did Cyclacel Pharmaceuticals pay the last dividend?

The last dividend was paid out on 8/1/2016.

What was the dividend of Cyclacel Pharmaceuticals in the year 2023?

In the year 2023, Cyclacel Pharmaceuticals distributed 0 USD as dividends.

In which currency does Cyclacel Pharmaceuticals pay out the dividend?

The dividends of Cyclacel Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Cyclacel Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Cyclacel Pharmaceuticals

Our stock analysis for Cyclacel Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cyclacel Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.